No association between the response to the addition of an atypical antipsychotic drug to an selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor and the brain-derived neurotrophic factor (Val66Met) polymorphism in refractory major depressive disorder in Japanese patients

Clinical Psychopharmacology and Neuroscience

Volumn 10, Issue 1, 2012, Pages 49-53

  Yoshimura, Reiji ^a   Kishi, Taro ^b,c   Hori, Hikaru ^a   Ikenouchi Sugita, Atsuko ^a   Umene Nakano, Wakako ^a   Katsuki, Asuka ^a   Hayashi, Kenji ^a   Iwata, Nakao ^c   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antipsychotic drug; Brain derived neurotrophic factor; Polymorphism; Selective serotonin reuptake inhibitor; Serotonin norepinephrine reuptake inhibitor; Treatment resistant depressive disorder

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BRAIN DERIVED NEUROTROPHIC FACTOR; DULOXETINE; FLUVOXAMINE; MILNACIPRAN; OLANZAPINE; PAROXETINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; DSM-IV; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPING TECHNIQUE; HAMILTON SCALE; HUMAN; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 84861374071     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2012.10.1.49     Document Type: Article

References (16)

1. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905-1917. (Pubitemid 44807782)
2. Kelsey JE. Switching drug class after initial SSRI failure. J Clin Psychiatry 1997;58:326-327. (Pubitemid 27362493)
3. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007;68:935-940. (Pubitemid 47015495)
4. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166:980-991.
5. Yoshimura R, Ikenouchi-Sugita A, Hori H, Umene-Nakano W, Katsuki A, Hayashi K, et al. Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:308-312.
6. Mowla SJ, Farhadi HF, Pareek S, Atwal JK, Morris SJ, Seidah NG, et al. Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor. J Biol Chem 2001;276:12660-12666.
7. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
8. Yoshimura R, Mitoma M, Sugita A, Hori H, Okamoto T, Umene W, et al. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1034-1037. (Pubitemid 46824019)
9. Yoshimura R, Nakano Y, Hori H, Ikenouchi A, Ueda N, Nakamura J. Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Hum Psychopharmacol 2006;21:433-438. (Pubitemid 44660182)
10. Rizos EN, Papadopoulou A, Laskos E, Michalopoulou PG, Kastania A, Vasilopoulos D, et al. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry 2008:1-5.
11. González-Pinto A, Mosquera F, Palomino A, Alberich S,Gutiérrez A, Haidar K, et al. Increase in brain-derivedneurotrophic factor in first episode psychotic patients aftertreatment with atypical antipsychotics. Int Clin Psychopharmacol 2010;25:241-245.
12. Hori H, Yoshimura R, Yamada Y, Ikenouchi A, Mitoma M, Ida Y, et al. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol 2007;22:21-27. (Pubitemid 44950764)
13. Chlan-Fourney J, Ashe P, Nylen K, Juorio AV, Li XM. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res 2002;954:11-20. (Pubitemid 35223437)
14. Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Katsuki A, Hayashi K, et al. Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. Hum Psychopharmacol 2012;27:33-38.
15. Zou YF, Ye DQ, Feng XL, Su H, Pan FM, Liao FF. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol 2010;20:535-544.
16. Yoshimura R, Kishi T, Suzuki A, Umene-Nakano W, Ikenouchi-Sugita A, Hori H, et al. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. Prog Neuropsychopharmacol Biol Psychiatry 2011;35: 1022-1025.